Nucala (mepolizumab) for injection, for subcutaneous use

Policy Number: MC/PC 028
Effective Date: June 1, 2025

Instructions for Use

Table of Contents **Page**

Related Policies

- N/A

Coverage Rationale

This policy is applicable to Nucala (mepolizumab) for injection, for subcutaneous use only.

Severe Asthma

For initial coverage of Nucala (mepolizumab) injection for Severe Asthma, the following will be required:

- Diagnosis of severe asthma **and**
- Asthma is an eosinophilic phenotype as defined by one of the following:
  - Baseline (pre-treatment) peripheral blood eosinophil level is greater than or equal to 150 cells/microliter.
  - Peripheral blood eosinophil levels were greater than or equal to 300 cells/microliter within the past 12 months **and**
- One of the following:
  - Patient has had at least two or more asthma exacerbations requiring systemic corticosteroids (e.g., prednisone) within the past 12 months **or**
  - Prior asthma-related hospitalization within the past 12 months **and**
- One of the following:
  - Both of the following:
    - Patient is 6 years of age or older but less than 12 years of age **and**
    - Patient is currently being treated with one of the following unless there is a contraindication or intolerance to these medications:
      - Both of the following:
        - Medium-dose inhaled corticosteroid (e.g., greater than 100 – 200 mcg fluticasone propionate equivalent/day)
        - Additional asthma controller medication (e.g., leukotriene receptor antagonist [LTRA] [e.g., montelukast], long-acting beta-2 agonist [LABA] [e.g., salmeterol], long-acting muscarinic antagonist [LAMA] [e.g., tiotropium]) **or**

- One medium dosed combination ICS/LABA pro
propionate 100mcg/ salmeterol 50mcg], Symb
4.5mcg] Breo Ellipta [fluticasone furoate 50 mcg/ vilanterol 25 mcg]) **or**

- Both of the following:
  - Patient is 12 years of age or older **and**
    - Both of the following:
      - High-dose inhaled corticosteroid (ICS) (e.g., greater than 500 mcg fluticasone propionate equivalent/day)
      - Additional asthma controller medication (e.g., leukotriene receptor antagonist [LTRA] [e.g., montelukast], long-acting beta-2 agonist [LABA] [e.g., salmeterol], long-acting muscarinic antagonist [LAMA] [e.g., tiotropium]) **or**
    - One maximally-dosed combination ICS/LABA product (e.g., Advair [fluticasone propionate 500mcg/ salmeterol 50mcg], Symbicort [budesonide 160mcg/ formoterol 4.5mcg], Breo Ellipta [fluticasone 200mcg/ vilanterol 25mcg]) **and**

- Prescribed by or in consultation with one of the following:
  - Pulmonologist
  - Allergist/Immunologist

For reauthorization coverage of Nucala (mepolizumab) injection for severe asthma, the following will be required:

- Patient demonstrates positive clinical response to therapy (e.g., reduction in exacerbations, improvement in forced expiratory volume in 1 second [FEV1], decreased use of rescue medications) **and**
- Patient continues to be treated with an inhaled corticosteroid (ICS) (e.g., fluticasone, budesonide) with or without additional asthma controller medication (e.g., leukotriene receptor antagonist [LTRA] [e.g., montelukast], long-acting beta-2 agonist [LABA] [e.g., salmeterol], long-acting muscarinic antagonist [LAMA] [e.g., tiotropium]) unless there is a contraindication or intolerance to these medications **and**
- Prescribed by or in consultation with one of the following:
  - Pulmonologist
  - Allergist/Immunologist

Chronic rhinosinusitis with nasal polyps (CRSwNP)

For initial coverage of Nucala (mepolizumab) injection for Chronic rhinosinusitis with nasal polyps (CRSwNP), the following will be required:

- Diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) **and**
- Patients is 18 years of age or older
- Unless contraindicated, the patient has had an inadequate response to 2 months of treatment with an intranasal corticosteroid (e.g., fluticasone, mometasone) **and**
- Used in combination with another agent for CRSwNP **and**
- Prescribed by or in consultation with one of the following:
  - Allergist/Immunologist
  - Otolaryngologist
  - Pulmonologist

For reauthorization coverage of Nucala (mepolizumab) injection for Chronic rhinosinusitis with nasal polyps (CRSwNP), the following will be required:

- Patient demonstrates positive clinical response to therapy (e.g., reduction in nasal polyps score [NPS; 0-8 scale], improvement in nasal obstruction symptoms via visual analog scale [VAS; 0-10 scale]) **and**
- Used in combination with another agent for CRSwNP **and**
- Prescribed by or in consultation with one of the following:

- Allergist/Immunologist
- Otolaryngologist
- Pulmonologist

Eosinophilic Granulomatosis with Polyangiitis (EGPA)

For initial coverage of Nucala (mepolizumab) injection for Eosinophilic Granulomatosis with Polyangiitis (EGPA), the following will be required:

- Diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) **and**
- Patient's disease has relapsed or is refractory to standard of care therapy (i.e., corticosteroid treatment with or without immunosuppressive therapy) **and**
- Patient is currently receiving corticosteroid therapy (e.g., prednisolone, prednisone) **and**
- Prescribed by or in consultation with one of the following:
  - Pulmonologist
  - Rheumatologist
  - Allergist/Immunologist

For reauthorization coverage of Nucala (mepolizumab) injection Eosinophilic Granulomatosis with Polyangiitis (EGPA), the following will be required:

- Patient demonstrates positive clinical response to therapy (e.g., increase in remission time)

Hypereosinophilic Syndrome (HES)

For initial coverage of Nucala (mepolizumab) injection for Hypereosinophilic Syndrome (HES), the following will be required:

- Diagnosis of hypereosinophilic syndrome (HES) **and**
- Patient is 12 years of age or older
- Patient has been diagnosed for at least 6 months **and**
- Verification that other non-hematologic secondary causes have been ruled out (e.g., drug hypersensitivity, parasitic helminth infection, HIV infection, non-hematologic malignancy) **and**
- Patient is Fip1-like1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA)-negative **and**
- Patient has uncontrolled HES defined as both of the following:
  - History of 2 or more flares within the past 12 months
  - Pre-treatment blood eosinophil count greater than or equal to 1000 cells/microliter **and**
- Trial and failure, contraindication, or intolerance to one of the following:
  - Corticosteroid therapy (e.g., prednisone)
  - Cytotoxic/immunosuppressive therapy (e.g., hydroxyurea, cyclosporine, imatinib) **and**
- Prescribed by or in consultation with one of the following:
  - Allergist/Immunologist
  - Hematologist

For reauthorization coverage of Nucala (mepolizumab) injection for Hypereosinophilic Syndrome (HES), the following will be required:

- Patient demonstrates positive clinical response to therapy (e.g., reduction in flares, decreased blood eosinophil count, reduction in corticosteroid dose)

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-

covered health service. Benefit coverage for health services is determined by t
document and applicable laws that may require coverage for a specific service
any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS Code	Description
J2182	Injection, mepolizumab, 1 mg

ICD-10 Code	Description
D72.11	Hypereosinophilic Syndrome
J31.0	Chronic rhinitis
J32.0	Chronic maxillary sinusitis
J32.1	Chronic frontal sinusitis
J32.2	Chronic ethmoidal sinusitis
J32.3	Chronic sphenoidal sinusitis
J32.4	Chronic pansinusitis
J32.8	Other chronic sinusitis
J32.9	Chronic sinusitis, unspecified
J33.0	Polyp of nasal cavity
J33.1	Polypoid sinus degeneration
J33.8	Other polyp of sinus
J33.9	Nasal polyp, unspecified
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation
J45.52	Severe persistent asthma with status asthmaticus
J82.81	Chronic eosinophilic pneumonia
J82.82	Acute eosinophilic pneumonia
J82.83	Eosinophilic asthma
J82.89	Other pulmonary eosinophilia, not elsewhere classified
M30.1	Polyarteritis with lung involvement [Churg-Strauss]

Background

Respiratory and allergy biologics are a mainstay of treatment for severe asthma, chronic rhinosinusitis with nasal polyposis, Eosinophilic Granulomatosis with Polyangiitis (EGPA) and hypereosinophilic syndrome (HES). Asthma is a chronic lung disease that inflames and narrows the airways, making it difficult to breathe. Asthma causes recurring periods of wheezing, chest tightness, shortness of breath, and coughing. In 2020, asthma affected an estimated 21 million adults and 4.2 million children in the United States (U.S.). Current pharmacologic options for asthma management are categorized as: (1) controller medications to achieve and maintain control of persistent asthma or prevent exacerbations, and (2) reliever medications for symptom relief and before exercise to prevent exercise-induced asthma symptoms (*Cloutier et al 2020, NHLBI 2007, Global Initiative for Asthma [GINA] 2024*). Severe asthma is defined as asthma that is uncontrolled despite adherence to maximal optimized high-dose ICS/LABA treatment or asthma that requires high doses of ICS/LABA to remain controlled (*GINA 2024*).

Chronic rhinosinusitis with nasal polyps (CRSwNP) has a prevalence of approxi[...]e sixth decade of life. Symptoms include nasal obstruction, reduced sense of sm[...] can substantially impact the quality of life. Most cases are idiopathic but may be due to genetic, metabolic, or immunologic causes, resulting in inflammation characterized by eosinophilia and elevated levels of IL-4, IL-5, and interleukin-13 (IL-13) (*Hopkins 2019*). Common treatment options for CRSwNP include saline irrigation and intranasal glucocorticoids in patients with mild symptoms, and short-term systemic glucocorticoids, surgery, and biologic agents in patients with severe symptoms (*Hopkins 2019*). Biologic agents that are FDA-approved for CRSwNP include dupilumab, mepolizumab, and omalizumab.

Eosinophilic Granulomatosis with Polyangiitis (EGPA), previously called Churg-Strauss syndrome, is a systemic necrotizing vasculitis that affects small-to-medium-sized vessels. It is typically associated with eosinophilia and severe asthma (*Chung et al 2021, Groh et al 2015, Padmanabhan et al 2019*). EGPA is a rare condition with a prevalence of approximately 13 cases per 1 million persons and an annual incidence of approximately 7 new cases per 1 million persons. It has a higher incidence in patients with asthma (*Groh et al 2015*). Systemic glucocorticoids are the mainstay of treatment for EGPA. For refractory EGPA, the addition of cyclophosphamide, azathioprine, mepolizumab, methotrexate, rituximab, or intravenous immunoglobulins (IVIG) can be considered (*Chung et al 2021, Groh et al 2015*). In more than 85% of patients with EGPA, remission can be achieved with glucocorticoids with or without an immunosuppressant; however, relapses occur in more than 33% of patients (*Pagnoux and Groh 2016*).

Hypereosinophilic Syndromes (HES) are disorders characterized by the overproduction of eosinophils, which causes organ damage (*Roufosse et al 2022*). Treatment for idiopathic HES may include systemic glucocorticoids, imatinib, hydroxyurea, interferon alfa, alemtuzumab, and Janus kinase inhibitors (e.g., tofacitinib and ruxolitinib). Additionally, mepolizumab was FDA-approved for HES in 2020.

Clinical Evidence

Asthma

The safety and efficacy of mepolizumab were evaluated in 3 double-blind, placebo-controlled, multicenter, RCTs in adolescent and adult patients with severe refractory asthma and signs of eosinophilic inflammation. Generally, patients were eligible for enrollment in the trials if they had eosinophils ≥ 150 cells/μL in the peripheral blood at screening or ≥ 300 cells/μL at some time during the previous year. Patients also were required to be on a high-dose ICS as well as another controller medication (*Bel et al 2014, Ortega et al 2014, Pavord et al 2012*). A systematic review and meta-analysis compared hospitalization or hospitalization and/or emergency room visit rates in patients with severe eosinophilic asthma treated with mepolizumab or placebo in addition to standard of care for ≥ 24 weeks. Four studies (N = 1388) were eligible for inclusion. Mepolizumab significantly reduced the rate of exacerbations requiring hospitalization (relative rate, 0.49; 95% CI, 0.30 to 0.80; p = 0.004) and hospitalization/emergency room visit (relative rate, 0.49; 95% CI, 0.33 to 0.73; p < 0.001) vs placebo (*Yancey et al 2017*).

Chronic rhinosinusitis with nasal polyps (CRSwNP)

SYNAPSE, a 52-week, double-blind, randomized, placebo-controlled, multicenter trial, evaluated the efficacy and safety of mepolizumab in adult patients with CRSwNP. A total of 407 patients with recurrent, refractory, severe, bilateral nasal polyp symptoms despite standard care treatment were enrolled. Patients were randomly assigned to receive 100 mg mepolizumab (n = 206) or placebo (n = 201) every 4 weeks. The total endoscopic nasal polyp score significantly improved from baseline with mepolizumab vs placebo (adjusted difference in medians, -0.73; 95% CI, -1.11 to -0.34; p < 0.0001). The nasal obstruction visual analogue score (VAS) score during weeks 49 to 52 also significantly improved (adjusted difference in medians, -3.14; 95% CI, -4.09 to -2.18; p < 0.0001) (*Han et al 2021*).

Eosinophilic Granulomatosis with Polyangiitis (EGPA)
A 52-week, randomized, placebo-controlled, double-blind, parallel-group, mult ficacy and safety of mepolizumab as add-on therapy (to glucocorticoid treatment, with or without immunosuppressive therapy) for patients with relapsing or refractory EGPA (*Wechsler et al 2017*). A total of 136 patients were randomly assigned to mepolizumab 300 mg every 4 weeks (n = 68) or placebo (n = 68). Results demonstrated the following for the mepolizumab and placebo groups, respectively: Percentage of patients with ≥ 24 weeks of accrued remission: 28% vs 3% (OR, 5.91; 95% CI, 2.68 to 13.03; p < 0.001).

Hypereosinophilic Syndrome (HES)
A 32-week, double-blind, placebo-controlled, multicenter, RCT evaluated the efficacy and safety of mepolizumab in patients ≥ 12 years with HES (without an identifiable nonhematologic secondary cause) for at least 6 months (*Nucala prescribing information 2021, Roufosse et al 2020*). A total of 108 patients were assigned to mepolizumab 300 mg every 4 weeks (n = 54) or placebo (n = 54). Results demonstrated that the proportion of patients with ≥ 1 HES flare or withdrew from the trial: 28% vs 56% (OR, 0.28; 95% CI, 0.12 to 0.64; p = 0.002).

Clinical Guidelines
The National Asthma Education and Prevention Program (NAEPP) guideline from the NHLBI states that the initial treatment of asthma should correspond to the appropriate asthma severity category, and it provides a stepwise approach to asthma management. Long-term control medications such as ICSs, long-acting bronchodilators, leukotriene modifiers, cromolyn, and immunomodulators should be taken daily on a long-term basis to achieve and maintain control of persistent asthma. ICSs are the most potent and consistently effective long-term asthma control medication. Quick-relief medications such as SABAs and anticholinergics are used to provide prompt relief of bronchoconstriction and accompanying acute symptoms such as cough, chest tightness, and wheezing. Systemic corticosteroids are important in the treatment of moderate or severe exacerbations because these medications prevent progression of the exacerbation, speed recovery, and prevent relapses (*NHLBI 2007*).

The 2024 GINA report also provides a stepwise approach to asthma management (*GINA 2024*). Treatment recommendations are based on patient age, and stepping down should be considered when asthma symptoms have been well-controlled and lung function have been stable for ≥ 3 months. ICS/beta2-agonist combination products are recommended for both controller (i.e., maintenance treatment) and reliever use in patients ≥ 6 years of age, while the preferred controller option in patients ≤ 5 years of age consists of low-dose ICS plus as-needed SABA as a reliever. In patients ≥ 6 years of age diagnosed with severe asthma and uncontrolled on Step 4 treatment phenotyping for Type 2 inflammation into categories such as severe allergic, aspirin-exacerbated, allergic bronchopulmonary aspergillosis, chronic rhinosinusitis, nasal polyposis, atopic dermatitis, or eosinophilic asthma is recommended. Add-on treatment with a biologic agent should be considered as follows:

- Severe allergic asthma: Anti-IgE treatment with omalizumab is recommended for patients ≥ 6 years of age.
- Severe eosinophilic asthma: Add-on anti-IL-5 therapy is recommended for patients ≥ 6 years of age (mepolizumab), ≥ 12 years of age (benralizumab), or ≥ 18 years of age (reslizumab).
- Severe eosinophilic/Type 2 asthma: Anti-IL4 therapy (dupilumab) is recommended for patients ≥ 6 years of age.
- Adults or adolescents requiring oral corticosteroids for maintenance therapy: Anti-IL4 therapy (dupilumab) is recommended.
- Severe asthma: Anti-TSLP therapy (tezepelumab-ekko) is recommended for patients ≥ 12 years of age.
- Prior to initiation of a biologic agent, several factors should be considered including cost, insurance eligibility criteria, evaluation of predictors of response, delivery route, dosing frequency, and patient preference.

The European Respiratory Society/American Thoracic Society guideline on the management of severe asthma suggests the use of anti-IL-5 therapy as an add-on in adults with severe uncontrolled eosinophilic asthma or severe corticosteroid-dependent asthma. A blood eosinophil count of ≥ 150 cells/µL is suggested as a cut-point to guide initiation of anti-IL-5 therapy in adults with severe asthma and prior exacerbations. A blood eosinophil count of ≥ 260 cells/µL or an exhaled

nitric oxide level of 19.5 parts per billion or greater may be used to identify adgic asthma who are likely to benefit from anti-IgE treatment (*Holguin et al 2020*).

Chronic rhinosinusitis with nasal polyps (CRSwNP)
Treatment of CRSwNP is addressed in guidelines from the American Academy of Otolaryngology-Head and Neck Surgery; American Academy of Allergy, Asthma & Immunology, the American College of Allergy, Asthma & Immunology, and the Joint Council of Allergy, Asthma & Immunology; the International Forum of Allergy & Rhinology; and the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) (*Orlandi et al 2016, Peters et al 2014, Rosenfeld et al 2015, Rank et al 2023*). Routine treatment recommendations include saline irrigation and/or intranasal glucocorticoids in patients with mild symptoms, and short-term systemic glucocorticoids and surgery in patients with severe or refractory symptoms. Biologics rather than no biologics are recommended for patients with CRSwNP (*Rank et al 2023*).

Eosinophilic Granulomatosis with Polyangiitis (EGPA)
In 2021, a joint guideline from the American College of Rheumatology and Vasculitis Foundation published recommendations for the management of EGPA along with other related conditions (*Chung et al 2021*). The following relevant conditional recommendations were provided:

- Patients with active, severe EGPA should be treated with cyclophosphamide or rituximab over mepolizumab for remission induction.
- Patients with severe EGPA whose disease has entered remission should be treated with methotrexate, azathioprine, or mycophenolate mofetil over mepolizumab for remission maintenance.
- Patients with EGPA who have experienced relapse with nonsevere disease manifestations (i.e., asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil: mepolizumab should be added over switching to another agent.
- Patients with EGPA who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving low-dose GCs and no other therapy: mepolizumab should be added over adding methotrexate, azathioprine, or mycophenolate mofetil.
- Patients with EGPA and high serum IgE levels who have experienced relapse with nonsevere disease manifestations (asthma and/or sinonasal disease) while receiving methotrexate, azathioprine, or mycophenolate mofetil: mepolizumab should be added over adding omalizumab.

Guidelines from the American Society for Apheresis recognized mepolizumab as a future treatment option, and the EGPA Consensus Task Force recommendations noted that mepolizumab held promise for this condition based on the pilot studies available at the time of guideline development. IVIG can be considered for refractory EGPA or for treatment during pregnancy (*Groh et al 2015, Padmanabhan et al 2019*).

Hypereosinophilic Syndrome (HES)
The World Health Organization (WHO) guidance on eosinophilic disorders have stated that identification of rearranged PDGFRA or PDGFRB is important in the management of eosinophilic disorders as those variants respond to imatinib (*Shomali and Gotlib 2021*). For patients with idiopathic HES (without imatinib-sensitive variants), corticosteroids are first-line therapy; second-line options include hydroxyurea, interferon-alfa, other cytotoxic chemotherapy agents, and hematopoietic stem cell transplantation. The WHO states that mepolizumab is FDA-approved for idiopathic HES, but other biologic agents are considered investigational.

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Nucala is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for:

• Add-on maintenance treatment of adult and pediatric patients aged 6 years a[illegible]:h an eosinophilic phenotype.
• Add-on maintenance treatment of adult patients 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP).
• The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).
• The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.

Limitations of use: Not for relief of acute bronchospasm or status asthmaticus.

References

1. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189-1197.
2. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken). 2021;73(8):1088-1105. doi:10.1002/acr.24634.
3. Cloutier MM, Dixon AE, Krishnan JA, et al. Managing asthma in adolescents and adults: 2020 asthma guideline update from the National Asthma Education and Prevention Program. JAMA. 2020;324(22):2301-2317. doi: 10.1001/jama.2020.21974.
4. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2024. http://www.ginasthma.org. Accessed April 0415, 2025.
5. Groh M, Pagnoux C, Baldini C, et al. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545-553.
6. Han JK, Bachert C, Fokkens W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;9(10):1141-1153. doi:10.1016/S2213-2600(21)00097-7.
7. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1). pii: 1900588. doi: 10.1183/13993003.00588-2019.
8. Hopkins C. Chronic Rhinosinusitis with Nasal Polyps. N Engl J Med. 2019;381(1):55-63. doi: 10.1056/NEJMcp1800215.
9. National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma (guideline on the Internet). 2007. https://www.ncbi.nlm.nih.gov/books/NBK7232/. Accessed April 04, 2025.
10. Nucala [package insert], Philadelphia, PA: GlaxoSmithKline LLC; March 2023.
11. Orlandi RR, Kingdom TT, Hwang PH, et al. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis. Int Forum Allergy Rhinol. 2016;6 Suppl 1:S22-209. doi: 10.1002/alr.21695.
12. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-1207.
13. Padmanabhan A, Connelly-smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34(3):171-354. doi: 10.1002/jca.21705.
14. Pagnoux C, Groh M. Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Expert Rev Clin Immunol;2016;12(10):1059-1067.
15. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-659.

16. Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinus Allergy Asthma Immunol. 2014;113(4):347-85. doi: 10.1016/j.anai.2014.07
17. Rank MA, Chu DK, Bognanni A, et al. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2023;151(2):386-398. doi:10.1016/j.jaci.2022.10.026.
18. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. Otolaryngol Head Neck Surg. 2015;152(2 Suppl):S1-S39. doi: 10.1177/0194599815572097.
19. Roufosse F, Kahn JE, Rothenberg ME, et al; HES Mepolizumab study group. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397-1405. doi: 10.1016/j.jaci.2020.08.037.
20. Roufosse F, Klion AD, Weller PF. Hypereosinophilic syndromes: treatment. UpToDate Web site. http://www.uptodate.com. Updated November 30, 2022. Accessed April 15, 2024.
21. Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(1):129-148. doi:10.1002/ajh.26352.
22. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017;376(20):1921-1932.
23. Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J Allergy Clin Immunol. 2017;139(4):1167-1175.

Policy History/Revision Information

Date	Summary of Changes
11/16/2023	Approved by OptumRx P&T Committee
05/16/2024	Annual Review. Updated language in coverage rationale section in line with drugs in the same class. Updated references.
05/15/2025	Annual Review. Updated language in coverage rationale section in line with drugs in the same class. Updated references.

Instructions for Use

This Medical Benefit Drug Policy provides assistance in interpreting standard benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. The insurance reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

OptumRx may also use tools developed by third parties to assist us in administering health benefits. OptumRx Medical Benefit Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

Archived Policy Versions (Internal Only)

Effective Date	Policy Number	Policy Title
mm/dd/yyyy – mm/dd/yyyy	######	Title of Policy Hyperlinked to KL or Other Internal Location

Nondiscrimination & Language Access Policy

Discrimination is Against the Law. Aspirus Health Plan, Inc. complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex, (including sex characteristics, including intersex traits; pregnancy or related conditions; sexual orientation, gender identity and sex stereotypes), consistent with the scope of sex discrimination described at 45 CFR § 92.101(a)(2). Aspirus Health Plan, Inc. does not exclude people or treat them less favorably because of race, color, national origin, age, disability, or sex.

Aspirus Health Plan, Inc.:
Provides people with disabilities reasonable modifications and free appropriate auxiliary aids and services to communicate effectively with us, such as:

- Qualified sign language interpreters.
- Written information in other formats (large print, audio, accessible electronic formats, other formats).

Provides free language assistance services to people whose primary language is not English, which may include:

- Qualified interpreters.
- Information written in other languages.

If *you* need reasonable modifications, appropriate auxiliary aids and services, or language assistance services, contact the Nondiscrimination Grievance Coordinator at the address, phone number, fax number, or email address below.

If *you* believe that Aspirus Health Plan, Inc. has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, *you* can file a *grievance* with:

Nondiscrimination Grievance Coordinator
Aspirus Health Plan, Inc.
PO Box 1890
Southampton, PA 18966-9998
Phone: 1-866-631-5404 (TTY: 711)
Fax: 763-847-4010
Email: customerservice@aspirushealthplan.com

You can file a *grievance* in person or by mail, fax, or email. If *you* need help filing a *grievance*, the Nondiscrimination Grievance Coordinator is available to help *you*.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201
1.800.368.1019, 800.537.7697 (TDD)

Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html. This notice is available at Aspirus Health Plan, Inc.'s website: https://aspirushealthplan.com/webdocs/70021-AHP-NonDiscrim_Lang-Assist-Notice.pdf.

Language Assistance Services

Albanian: KUJDES: Nëse flitni shqip, për ju ka në dispozicion shërbime të asistencës gjuhësore, pa pagesë.Telefononi në 1-800-332-6501 (TTY: 711).

Arabic تنبيه: إذا كنت تتحدث اللغة العربية، فإن خدمات المساعدة اللغوية متاحة لك مجاناً. اتصل بن اعلى رقم الهاتف1-800-332-6501(رقم هاتف الصم والبك : 711)

French: ATTENTION: Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 1-800-332-6501 (ATS: 711).

German: ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zurVerfügung. Rufnummer: 1-800-332-6501 (TTY: 711).

Hindi: _यान द_: य_द आप ि हंदी बोलते ह_ तो आपके ि लए मु_त म_ भाषा सहायता सेवाएं उपल_ध ह_।1-800-332-6501 (TTY: 711) पर कॉल कर_।

Hmong: LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1-800-332-6501 (TTY: 711).

Korean: 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다.1-800-332-6501 (TTY: 711)번으로 전화해 주십시오.

Polish: UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer1-800-332-6501 (TTY: 711).

Russian: ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода.Звоните 1-800-332-6501 (телетайп: 711).

Spanish: ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al1-800-332-6501 (TTY: 711).

Tagalog: PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nangwalang bayad. Tumawag sa 1-800-332-6501 (TTY: 711).

Traditional Chinese: 注意：如果您使用繁體中文， 您可以免費獲得語言援助服務。請 致電 1-800-332-6501 (TTY: 711)

Vietnamese: CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1-800-332-6501 (TTY: 711).

Pennsylvania Dutch: Wann du Deitsch (Pennsylvania German / Dutch) schwetzscht, kannscht du mitaus Koschte ebbergricke, ass dihr helft mit die englisch Schprooch. Ruf selli Nummer uff: Call 1-800-332-6501 (TTY: 711).

Lao: ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ,ໂດຍບໍ່ເສັງຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທຣ 1-800-332-6501 (TTY: 711).